-
Je něco špatně v tomto záznamu ?
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis
T. Yanagisawa, K. Mori, S. Katayama, H. Mostafaei, F. Quhal, E. Laukhtina, P. Rajwa, RS. Motlagh, A. Aydh, F. König, NC. Grossmann, B. Pradere, J. Miki, M. Schmidinger, S. Egawa, SF. Shariat
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, metaanalýza, přehledy
PubMed
35465726
DOI
10.2217/imt-2021-0207
Knihovny.cz E-zdroje
- MeSH
- biologické markery MeSH
- inhibitory kontrolních bodů terapeutické užití MeSH
- karcinom z renálních buněk * diagnóza farmakoterapie MeSH
- lidé MeSH
- lymfocyty patologie MeSH
- nádory ledvin * MeSH
- neutrofily patologie MeSH
- prognóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- přehledy MeSH
Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Methods: PubMed, Web of Science and Scopus databases were searched for articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results: Fifteen studies comprising 1530 patients were eligible for meta-analysis. High levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein and lactate dehydrogenase were significantly associated with worse progression-free survival. High NLR and PLR were significantly associated with worse overall survival. Conclusion: High pretreatment NLR and PLR appear to be hematological prognostic factors of progression and overall mortality in mRCC patients treated with ICIs. These findings might help in the design of correlative biomarker studies to guide the clinical decision-making in the immune checkpoint inhibitor era.
Department of Urology 2nd Faculty of Medicine Charles University Prague 11638 Czech Republic
Department of Urology Comprehensive Cancer Center Medical University of Vienna Vienna 1090 Austria
Department of Urology King Fahad Specialist Hospital Dammam 32253 Saudi Arabia
Department of Urology King Faisal Medical City Abha 614312 Saudi Arabia
Department of Urology Luzerner Kantonsspital Lucerne 6004 Switzerland
Department of Urology Medical University of Silesia Zabrze 41 808 Poland
Department of Urology The Jikei University School of Medicine Tokyo105 8461 Japan
Department of Urology University Hospital Zurich Zurich 8091 Switzerland
Department of Urology University Medical Centre Hamburg Eppendorf Hamburg 20251 Germany
Department of Urology University of Texas Southwestern Medical Center Dallas TX 75390 USA
Department of Urology Weill Cornell Medical College New York NY 10021 USA
Institute for Urology and Reproductive Health Sechenov University Moscow 119991 Russia
Karl Landsteiner Institute of Urology and Andrology Vienna 1010 Austria
Research Center for Evidence Based Medicine Tabriz University of Medical Sciences Tabriz 5166 Iran
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018179
- 003
- CZ-PrNML
- 005
- 20220804134614.0
- 007
- ta
- 008
- 220720s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/imt-2021-0207 $2 doi
- 035 __
- $a (PubMed)35465726
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Yanagisawa, Takafumi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo105-8461, Japan $1 https://orcid.org/0000000274100712
- 245 10
- $a Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis / $c T. Yanagisawa, K. Mori, S. Katayama, H. Mostafaei, F. Quhal, E. Laukhtina, P. Rajwa, RS. Motlagh, A. Aydh, F. König, NC. Grossmann, B. Pradere, J. Miki, M. Schmidinger, S. Egawa, SF. Shariat
- 520 9_
- $a Aim: We aimed to assess the prognostic value of pretreatment hematological biomarkers in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs). Methods: PubMed, Web of Science and Scopus databases were searched for articles according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement. Results: Fifteen studies comprising 1530 patients were eligible for meta-analysis. High levels of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein and lactate dehydrogenase were significantly associated with worse progression-free survival. High NLR and PLR were significantly associated with worse overall survival. Conclusion: High pretreatment NLR and PLR appear to be hematological prognostic factors of progression and overall mortality in mRCC patients treated with ICIs. These findings might help in the design of correlative biomarker studies to guide the clinical decision-making in the immune checkpoint inhibitor era.
- 650 _2
- $a biologické markery $7 D015415
- 650 12
- $a karcinom z renálních buněk $x diagnóza $x farmakoterapie $7 D002292
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a inhibitory kontrolních bodů $x terapeutické užití $7 D000082082
- 650 12
- $a nádory ledvin $7 D007680
- 650 _2
- $a lymfocyty $x patologie $7 D008214
- 650 _2
- $a neutrofily $x patologie $7 D009504
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Mori, Keiichiro $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, The Jikei University School of Medicine, Tokyo105-8461, Japan $1 https://orcid.org/0000000261476569
- 700 1_
- $a Katayama, Satoshi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama, 700-8558, Japan $1 https://orcid.org/0000000283772457
- 700 1_
- $a Mostafaei, Hadi $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, 5166, Iran $1 https://orcid.org/0000000155961771
- 700 1_
- $a Quhal, Fahad $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, King Fahad Specialist Hospital, Dammam, 32253, Saudi Arabia $1 https://orcid.org/0000000281636953
- 700 1_
- $a Laukhtina, Ekaterina $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $1 https://orcid.org/0000000289530272
- 700 1_
- $a Rajwa, Pawel $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, Medical University of Silesia, Zabrze, 41-808, Poland $1 https://orcid.org/0000000340736584
- 700 1_
- $a Motlagh, Reza S $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Men's Health & Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran $1 https://orcid.org/0000000238199911
- 700 1_
- $a Aydh, Abdulmajeed $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, King Faisal Medical City, Abha, 614312, Saudi Arabia $1 https://orcid.org/0000000160786816
- 700 1_
- $a König, Frederik $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, University Medical Centre Hamburg-Eppendorf, Hamburg, 20251, Germany $1 https://orcid.org/0000000233879029
- 700 1_
- $a Grossmann, Nico C $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Department of Urology, University Hospital Zurich, Zurich, 8091, Switzerland $u Department of Urology, Luzerner Kantonsspital, Lucerne, 6004, Switzerland $1 https://orcid.org/0000000186986461
- 700 1_
- $a Pradere, Benjamin $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $1 https://orcid.org/0000000277688558
- 700 1_
- $a Miki, Jun $u Department of Urology, The Jikei University School of Medicine, Tokyo105-8461, Japan $1 https://orcid.org/0000000246388640
- 700 1_
- $a Schmidinger, Manuela $u Department of Medicine I & Comprehensive Cancer Center, Clinical Division of Oncology, Medical University of Vienna, Vienna, 1090, Austria
- 700 1_
- $a Egawa, Shin $u Department of Urology, The Jikei University School of Medicine, Tokyo105-8461, Japan $1 https://orcid.org/0000000291985559
- 700 1_
- $a Shariat, Shahrokh F $u Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria $u Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia $u Division of Urology, Hourani Center for Applied Scientific Research, Al-Ahliyya Amman University, Amman, 19328, Jordan $u Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA $u Department of Urology, Second Faculty of Medicine, Charles University, Prague, 11638, Czech Republic $u Department of Urology, Weill Cornell Medical College, New York, NY 10021, USA $u Karl Landsteiner Institute of Urology & Andrology, Vienna, 1010, Austria $1 https://orcid.org/0000000266276179
- 773 0_
- $w MED00175821 $t Immunotherapy $x 1750-7448 $g Roč. 14, č. 9 (2022), s. 709-725
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35465726 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134607 $b ABA008
- 999 __
- $a ok $b bmc $g 1821987 $s 1169422
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 14 $c 9 $d 709-725 $e 20220425 $i 1750-7448 $m Immunotherapy $n Immunotherapy $x MED00175821
- LZP __
- $a Pubmed-20220720
